SCHEMBL2009256

SCHEMBL2009256

NC(=O)CCCCOS(=O)(=O)c1ccc(-c2ccc(C(=O)O)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 8/20 0.51
CA2 P00918 8/20 0.51
CA9 Q16790 8/20 0.51
CA12 O43570 6/20 0.51
CA14 Q9ULX7 6/20 0.51
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
STAT3 P40763 1/20 0.44
CA3 P07451 1/20 0.44
CA6 P23280 1/20 0.44
CYP2C19 P33261 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
RARB P10826 4/20 0.43
F2 P00734 2/20 0.42
PRSS1 P07477 2/20 0.42
PRSS2 P07478 2/20 0.42
PRSS3 P35030 2/20 0.42
MMP2 P08253 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2004234 0.88 MMP2 (0.50) CA1CA2CA9CA12MMP2
SCHEMBL2012396 0.87 MEN1 (0.50) CA1CA2CA9CA12CA14
SCHEMBL2013462 0.85 LMNA (0.42) CA1CA2CA9CA12CA14
SCHEMBL2009235 0.84 ALDH1A1 (0.47) CA1CA9CA12KMT2ASTAT3
SCHEMBL2008430 0.84 MEP1B (0.40) F2PRSS1PRSS2PRSS3MMP2
SCHEMBL2005594 0.84 MMP2 (0.51) CA1CA2CA9CA12CA14
SCHEMBL2006904 0.81 MMP3 (0.50) CA1CA2CA9CA12MMP2
SCHEMBL2009137 0.81 HDAC1 (0.42) CA1CA2CA9CA12MEN1
SCHEMBL2008347 0.80 CA12 (0.48) CA1CA2CA9CA12MEN1
SCHEMBL2011339 0.80 KIF11 (0.41) MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964643-B2 Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2011-06-21 US disclosed
EP-1756046-B1 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS UNIV ABERDEEN (GB) 2009-12-09 EP disclosed
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2008-05-22 US disclosed
EP-1756046-A2 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS The University Court of The University of Aberdeen (GB) 2007-02-28 EP disclosed
WO-2005118528-A2 ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119555-A1 Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions ARSA, CNKSR1, BCL9L CA1 675/4885CA2 715/4885CA9 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.